All In Biotech

Drug Trial Radar · NCT05573464

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Randomized, Double-Blind, 12-Week (With an Extension to 52 Weeks in a Subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared to BGF Delivered by MDI HFA in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 559 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

559

Actual

Start

Sep 27, 2022

Primary completion

Mar 26, 2024

Study completion Mar 26, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with moderate to very severe COPD.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • BGF MDI HFO 320/14.4/9.6 μgDrug

    Budesonide, Glycopyrronium, and Formoterol Fumarate

  • BGF MDI HFA 320/14.4/9.6 μgDrug

    Budesonide, Glycopyrronium, and Formoterol Fumarate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and Percentage of Participants With Serious Adverse EventsTime frame: Over 12 weeks
  2. Number and Percentage of Participants With Serious Adverse EventsTime frame: Over 52 weeks
  3. Number and Percentage of Participants With Non-serious Adverse Events >5%Time frame: Over 12 weeks
  4. Number and Percentage of Participants With Non-serious Adverse Events >5%Time frame: Over 52 weeks
  5. Number and Percentage of Participants With Adverse Events of Special InterestTime frame: Over 12 weeks
  6. Number and Percentage of Participants With Adverse Events of Special InterestTime frame: Over 52 weeks

Locations

91 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Newport Beach, California

  • Research Site

    Miami, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Valparaiso, Indiana

  • Research Site

    Crowley, Louisiana

  • Research Site

    North Dartmouth, Massachusetts

  • Research Site

    St Louis, Missouri

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Dublin, Ohio

  • Research Site

    Grants Pass, Oregon

  • Research Site

    Portland, Oregon

  • Research Site

    Anderson, South Carolina

  • Research Site

    Columbia, South Carolina

  • Research Site

    Gaffney, South Carolina

  • Research Site

    Longview, Texas

  • Research Site

    McKinney, Texas

  • Research Site

    Richmond, Virginia

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Quilmes, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Fernando, Argentina

  • Research Site

    Blagoevgrad, Bulgaria

  • Research Site

    Dupnitsa, Bulgaria

  • Research Site

    Lom, Bulgaria

  • Research Site

    Pernik, Bulgaria

  • Research Site

    Sandanski, Bulgaria

  • Research Site

    Sevlievo, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Veliko Tarnovo, Bulgaria

  • Research Site

    Vidin, Bulgaria

  • Research Site

    Truro, Nova Scotia, Canada

  • Research Site

    Ajax, Ontario, Canada

  • Research Site

    Burlington, Ontario, Canada

  • Research Site

    Guelph, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.